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Abstract
Objectives. To identify serum sphingolipids that could act as candidate biomarkers in RA.
Methods. We performed lipidomic analyses in the serum of 82 participants: 19 established RA patients, 18 un-
treated early RA patients, 13 untreated early arthritis patients not fulfilling the classification criteria for RA, 12 estab-
lished SpA patients and 20 controls. We compared the lipid levels from the different patient groups with the control
group through multiple-regression analyses controlling for age at diagnosis, gender and medication (cDMARDs and
corticoids).
Results. Established RA patients had significantly increased levels of sphingosine, monohexosylceramide and
ceramide compared with controls, when controlling for age and gender. Monohexosylceramide levels remained sig-
nificantly increased when additionally controlling for medication. On the contrary, SpA patients had significantly
decreased levels of ceramide, in both analyses.
Conclusion. We observed a detectable increase in the levels of certain sphingolipids in the serum of established
RA patients when compared with controls, in line with previous observations in the synovial fluid. Such findings
provide further evidence that sphingolipids may play a key role in the pathophysiology of RA.
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Introduction
The landscape of possible biomarker candidates in RA
is relatively narrow [1]. The identification of RA bio-
markers with applicability to early diagnosis and
treatment stratification is therefore a relevant, unmet
medical need [2].
There is preliminary evidence that sphingolipids might
be relevant in the pathophysiology of RA [3–7]. A previ-
ous report described that the sphingolipid pathway regu-
lating the intracellular levels of ceramide (Cer) and
sphingosine-1-phosphate (S1P) is dysregulated in RA
fibroblast-like synoviocytes [3]. In addition, sphingolipids
have pleotropic pro-inflammatory effects through the in-
duction of cyclooxygenase-2 and through genes encod-
ing pro-inflammatory cytokines [4]. The membrane-bound
glycosphingolipid GM3, moreover, is involved in the con-
trol of the activation of T cells in an animal model of arth-
ritis [5] and of osteoclastogenesis in an animal model of
multiple myeloma [6]. Additionally, the levels of lipid spe-
cies, including sphingolipids, have been reported to be
increased in the SF of RA and osteoarthritis patients [7].
Considering the aforementioned evidence, we hypothe-
sized that the contribution of sphingolipids to inflamma-
tory processes would likely be detectable in the serum of
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. We observed an increase in certain serum sphingolipid levels of established RA patients.
. This finding is consistent with previously reported increases in the synovial fluid of RA patients.
. We provide, therefore, further evidence on the implication of sphingolipids in the pathophysiology of RA.
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de Lisboa, 2Laboratório de Genética, Faculdade de Medicina,
Universidade de Lisboa, Lisbon, Portugal, 3Department of
Neurology, Ludwig-Maximilians-Universität München, Munich,
Germany, 4Rheumatology Department, Hospital Santa Maria,
Centro Hospitalar Universitário Lisboa Norte, EPE (CHLN), Lisbon,
Portugal, 5Genetics and Molecular Pathology, SA Pathology at
Women’s and Children’s Hospital, North Adelaide and School of
Medicine, University of Adelaide, Adelaide, Australia and 6Instituto
de Bioquı́mica, Faculdade de Medicina, Universidade de Lisboa,
Lisbon, Portugal
Submitted 17 June 2019; accepted 9 October 2019
Correspondence to: Gabriel Miltenberger-Miltenyi, MD, PhD, Instituto
de Medicina Molecular Jo~ao Lobo Antunes, Faculdade de Medicina,
Universidade de Lisboa, Centro Académico de Medicina de Lisboa,

























atology/kez545/5662428 by guest on 07 D
ecem
ber 2019
RA patients and thus, that serum sphingolipids could
eventually act as candidate biomarkers in RA.
Methods
Patient and sample selection
Eighty-two participants were included in the study. We
collected information on age and gender from all partici-
pants. In addition, we collected information on age-of-
onset, disease duration, DAS-28, RF, ACPA, HLA B27
and ongoing treatment of the patients by the time of the
blood collection.
Participants were divided into five groups (Table 1,
including demographic-, clinical- and medication data):
untreated early RA patients (<1 year of disease duration)
(n¼18); established active RA patients [>1 year after
disease onset, DAS-28>3.2, under treatment with con-
ventional disease-modifying antirheumatic drugs
(cDMARDs) and corticoids (low-dose prednisolone
<10mg/day)] (n¼ 19); untreated early arthritis patients
not fulfilling the classification criteria for RA (<1 year
after disease onset) (n¼ 13); established active SpA
patients with peripheral symptoms (>1 year after disease
onset, under NSAID treatment) (n¼12); and healthy con-
trols (n¼ 20).
Patients were classified as RA if they fulfilled the
ACR/EULAR 2010 classification criteria [8] and were
classified as SpA if they fulfilled the ASAS 2011 classifi-
cation criteria [9]. Exclusion criteria were applied
accordingly.
Early RA patients had not been previously on
cDMARD or corticoid treatment, because the diagnosis
of RA was set solely at the first assessment in our de-
partment. Patients and controls did not carry any rele-
vant concomitant condition to this study, such as
hepatitis related to HBV and HCV infection, diabetes,
lysosomal storage diseases and Parkinson’s disease (as
also discussed below).
All participants signed informed consent, and the
study was approved by the Ethics Committee of the
Centro Académico de Medicina de Lisboa. Serum sam-
ples were collected between 2005 and 2017 and stored
at –80C at Biobanco-IMM, Centro Académico de
Medicina de Lisboa. Transportation of the samples to
the laboratory was carried out on dry ice.
Lipid measurements
We screened the serum levels of total Cer (as a sum of
Cer 16:0, Cer 18:0, Cer 20:0, Cer 22:0, Cer 23:0, Cer
24:0, Cer 24:1, Cer 25:0 and Cer 26:0), total monohexo-
sylceramide (HexCer; as a sum of HexCer 16:0, HexCer
16:1, HexCer 18:0, HexCer 20:0, HexCer 22:0, HexCer
23:0, HexCer 24:0 and HexCer 24:1) and sphingosine
(So; d18:1) in 10 mL of serum by liquid chromatography
electrospray ionization tandem mass spectrometry (LC-
ESI-MS/MS) as previously described [10]. All samples
were analysed in duplicate.
Statistics
We carried out multiple regressions on the serum lipid
levels (Cer, HexCer and So; dependent variables) using
two types of models, which were highly complementary.
TABLE 1 Raw demographic, clinical, medication data and serum sphingolipid levels of the patient and control groups
Early non-RA Established RA Early RA Established SpA Controls
(n 5 13) (n 5 19) (n 5 18) (n 5 12) (n 5 20)
Demographic data
Age 45 (12) 63 (11) 58 (16) 47 (15) 59 (2)
Gender (F/M) 6/7 5/14 4/14 8/4 5/15
Clinical data
RF (%) 16.7 61.1 77.8 n.a. n.a.
ACPA (%) 14.3 85.7 61.1 n.a. n.a.
HLA B27 (%) n.a. n.a. n.a. 8.3 n.a.
DAS-28 4.47 (1.56) 5.01 (1.08) 4.79 (1.19) 4.01 (0.66) n.a.
Medication
cDMARDs (yes/total) 0/13 19/19 0/18 2/12 0/20
Corticoids (yes/total) 0/13 19/19 0/18 1/12 0/20
Continuous NSAIDs (yes/total) 0/13 0/19 0/18 12/12 0/20
Lipid levels (nmol/mL)
Cer 8.07 (1.48) 8.42 (2.22) 7.41 (1.67) 6.23 (1.53) 7.57 (1.62)
HexCer 18.58 (6.77) 17.50 (6.11) 12.90 (4.23) 15.74 (6.93) 14.61 (2.92)
So 0.14 (0.04) 0.20 (0.11) 0.15 (0.03) 0.13 (0.03) 0.13 (0.03)
Ages are presented as mean (S.D.). RF, ACPA and HLA-B27 are presented as % of positive measurements. DAS-28 is
expressed as mean (S.D.), including in SpA patients, all with peripheral symptoms, as well. Lipid levels are presented as
mean (S.D.) of the two measurements of each lipid per subject in each group. Results from the statistical analyses of the
lipid levels are presented in Table 2. F, female; M, male; n.a., not applicable; cDMARDs, conventional DMARDs; Cer,
ceramide; HexCer, monohexosylceramide; So, sphingosine.
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As independent variables in the first type of models, we
included each participant’s group (with the patient
groups being coded categorically and no term being
added for the control group), age at diagnosis and gen-
der (coded as 0 or 1 for males and females, respective-
ly), in addition to an intercept term and a variable that
accounted for the fact that each sample was analysed
twice (rep, coded as 0 or 1 for the first and second
measurements, respectively).
In the second type of models, we included addition-
ally the treatments with cDMARDs and corticoids as in-
dependent variables (both coded as 1 or 0, depending
on whether a given patient was, or was not, on
cDMARDs or corticoid medication, respectively). To fa-
cilitate the interpretation of the estimated coefficients,
we normalized all variables so that their absolute val-
ues were always lower than, or equal to, 1. Our analy-
ses did not explicitly consider disease duration or other
clinical data because such information was intrinsically
related to the grouping of the patients and/or unavail-
able for controls. Similarly, we did not consider NSAID
treatment in our models, as only the SpA patients were
continuously on this medication (Table 1). We applied
Bonferroni correction for multiple comparisons within
each type of analyses.
Results
We found increased levels of So, HexCer and Cer in
established RA patients vs controls, with the increase in
So being the most significant [coefficient value (cv):
0.106, P <0.001; Table 2, column A], followed by the
increase of HexCer (cv: 0.077, P <0.01; Table 2, column
A), both of which remained significant after Bonferroni
correction. Early RA patients, likewise, showed a signifi-
cant increase in So vs controls (cv: 0.043, P ¼0.042;
Table 2, column A), although that increase did not sur-
vive Bonferroni correction. On the contrary, the estab-
lished SpA group showed solely decreased levels of Cer
compared to the control group (cv: –0.091, P ¼0.005;
Table 2, column A).
When additionally controlling for cDMARDs and corti-
coids, the increase of So remained significant in the
early RA patients, although significance was lost
after Bonferroni correction (cv: 0.043, P ¼0.042;
Table 2, column B). Besides, the increase of So lost
statistical power in the established RA group (cv:
0.089, P ¼0.342; Table 2, column B). In the established
RA group, however, levels of HexCer remained
significantly increased when compared to the control
group (cv: 0.347, P ¼0.008; Table 2, column B).
Furthermore, like in the first model type, Cer levels
remained significantly lower in SpA patients than in
controls (cv: -0.093, P ¼0.008; Table 2, column B).
Still, no cut-off levels could be proposed that could be
of interest for diagnosis.
In the second model type, age and corticoid therapy
were also shown to be negatively associated with
HexCer (Table 2, column B), but none of these findings
survived Bonferroni correction. Notably, no significant
difference was detected between the first and the se-
cond measurements of each lipid for any model (all
P >0.25).
TABLE 2 Serum lipid level alterations in the different patient groups compared with the control group
Dependent variables Cer HexCer So
Independent variables \ Model type A B A B A B
Intercept 0.479*** 0.483*** 0.445*** 0.469*** 0.118** 0.121**
Early non-RA 0.029 0.028 0.074* 0.067 0.043 0.042
Established RA 0.055* 0.066 0.077* 0.347** 0.106*** 0.089
Early RA 0.010 0.010 0.043 0.044 0.043* 0.043*
Established SpA 0.091** 0.093** 0.007 0.027 0.031 0.027
Rep 0.018 0.018 0.016 0.016 0.010 0.010
Age 0.005 0.011 0.128 0.161* 0.096 0.091
Gender 0.012 0.013 0.004 0.010 0.014 0.013
cDMARDs — 0.010 — 0.066 — 0.024
Corticoids — 0.021 — 0.203* — 0.007
Results obtained, when controlling for the measurement number (1st, 2nd) of each lipid, age and gender, and either not
controlling (columns A) or controlling (columns B) for both conventional disease-modifying antirheumatic drugs (cDMARDs)
and corticoids effects. Effects of the independent variables on the lipid levels (dependent variables) are expressed by the
corresponding estimated regression coefficients (cv), with positive (negative, respectively) coefficients meaning that higher
values of the independent variables are associated with higher (lower, respectively) values of the lipid levels. All variables
were scaled so that their maximum absolute value was equal to 1. Patients’ gender was coded with 0 (male) or 1 (female);
‘rep’ relates to the measurement number of the respective lipid (0 and 1 for the first and second measurements, respect-
ively). *, ** and *** denote P < 0.05, P < 0.01, and P < 0.001, respectively. Coefficients with P-values below <0.05/3 (i.e.
surviving Bonferroni correction) are shown in bold. cDMARDs, conventional DMARDs; Cer, ceramide; HexCer, monohexo-
sylceramide; So, sphingosine.













We observed an increase in the levels of certain sphin-
golipids in the serum of established RA patients com-
pared to controls, with the increase in So having the
highest magnitude and the increase in HexCer being the
most robust, given that this increase was significant
both when not controlling and when controlling for medi-
cation effects.
Taking into account that only the increase in the
HexCer levels remained significant when controlling for
medication, it is hard to conclude, at this moment,
whether the other sphingolipid levels were increased due
to disease-related aspects or rather due to medication
effects. Previous studies on RA and other diseases [7,
11–14], however, suggest that the reported increases
might have appeared due to disease progression; indeed,
our second type of models suffered from lack of power
due to the strong correlation between the patients’ group
and their medication variables (see Table 1).
Sphingolipids have started to be identified as potential
serum biomarkers in various diseases such as hepatitis
related to HBV and HCV infection [11], Type I diabetes
[12], lysosomal storage diseases [13], or Parkinson’s
disease [14]. Less is known about sphingolipids in RA. A
3-fold increase in the Cer concentration and a 5.8-fold
increase in the HexCer concentration were observed in
the SF of RA patients when compared with controls [7].
In an arthritic rat model, serum Cer, HexCer, So and
S1P were up-regulated, while sphingomyelins were
down-regulated when compared with the respective
control animal group [15]. In addition, higher activity of
the serum secretory sphingomyelinase (S-SMase) en-
zyme was reported in patients with RA [16]. S-SMase is
an extracellular member of sphingomyelinases, enzymes
that hydrolyze sphingomyelin to Cer, and activation of
SMases is pivotal for ceramide production during inflam-
mation [16].
The influence of the combined therapy with cDMARDs
and corticoids on sphingolipid serum levels is still un-
clear. MTX was found to decrease Cer-16 levels in can-
cer cell lines in vitro [17] and the influence of MTX on
sphingolipids was reported in a metabolomics study in
an arthritic murine model [18]. Notably, in the aforemen-
tioned study of sphingolipids in the SF of RA patients,
only the treatment with intra articular corticoids was an
exclusion criterion, so probably most patients were also
on MTX and low-dose corticoids [7].
We found reduced levels of Cer in SpA patients, who
were all on continuous treatment with NSAIDs. This ob-
servation relates with the findings of the above-
mentioned study of sphingolipid profiling in RA rats,
where treatment with the NSAID indomethacin reversed
the increased levels of Cer and its metabolites to control
levels [15].
The literature is very limited about sphingolipid level
changes in the serum and brain during physiological
aging in humans. Czubowicz et al. described that Cer
increases, while S1P decreases, with age in the brain
[19], and increased sphingomyelin levels were described
with increased age in the Baltimore Longitudinal Study
of Aging [20]. In our study, age had a negative associ-
ation with HexCer, although this did not survive correc-
tion for multiple comparisons, which suggests the need
for further studies.
In summary, we could detect significantly higher levels
of sphingolipids (most notably HexCer) in the serum of
established RA patients as compared with controls. This
elevation is consistent with the known roles of sphingoli-
pids in inflammation and is in agreement with previous
findings in the SF of patients with RA, underlining the
contribution of sphingolipids to the pathophysiology of
RA. Nevertheless, as in early RA our findings were less
consistent than those that we saw in established RA,
the significance of serum sphingolipids as clinically use-
ful biomarkers for RA remains unproven and its possible
relationship with the cytokine environment of the differ-
ent phases of the disease still has to be clarified.
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